Only 12.60% of the stock of Athersys is held by insiders. Its current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders and certain pulmonary conditions. Athersys has received 310 “underperform” votes.
Thank you for standing by, and welcome to the Athersys second-quarter 2020 results Conference Call. What this means: Athersys Inc (ATHX) gets an Overall Rank of 64, which is an above average rank under InvestorsObserver's stock ranking system. Athersys, Inc. was founded in 1995 and is headquartered in Cleveland, Ohio.Stats based on trailing-twelve-month (ttm) numbers. Find the latest analyst research for Athersys, Inc. Common Stock (ATHX) at Nasdaq.com. Get detailed information on Athersys stock (NASDAQ: ATHX), including today’s stock quote, real-time price, financial history, charts, and more.
It is focused on developing novel and proprietary therapies in the areas where there is a significant unmet medical need, particularly in the regenerative medicine area. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. Copyright © 2018. Athersys Inc. ATHX Morningstar Rating Rating as of Jun 9, 2020. The firm's main product is Multistem cell therapy. The company has license and collaboration agreements with Healios K.K. Athersys Inc is a clinical-stage biotechnology company. Portfolio results are unaudited and based on varying investment expiration dates. On 11-08-2020 (Tuesday), ATHX stock construct a change of -12.74 in a total of its share price and finished its trading at 2.26. Quote Stock Analysis News Price vs Fair Value Trailing Returns Financials …
Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services.Athersys Inc. is a biopharmaceutical company that is focused in the field of regenerative medicine. Retirement Community Sentiment. As Jesse mentioned, I'm Karen Hunady, director of corporate communications and investor relations for Athersys. See you at the top! MarketBeat's community ratings are surveys of what our community members think about Athersys and other stocks.
The Ascent is The Motley Fool's new personal finance brand devoted to helping you live a richer life. It is engaged in the discovery and development of best-in-class therapies designed to extend and enhance the quality of human life. What this means: Athersys Inc (ATHX) gets a very positive evaluation from InvestorsObserver's ranking system. Athersys Inc. ATHX Morningstar Rating Rating as of Jun 9, 2020. The single most important factor in a company's success is the team that's leading the company Technical Analysis Summary for Athersys Inc with Moving Average, Stochastics, MACD, RSI, Average Volume. With its Forward Dividend at 0 and a yield of 0%, the company’s investors could be worried for the ATHX stock to lose ahead of the earnings release. See Athersys, Inc. (ATHX) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. All Rights Reserved. Athersys, has a market cap of $440.61 Million and is expected to release its quarterly earnings report on Nov 04, 2020- Nov 09, 2020. Currency in USD
ATHX | Complete Athersys Inc. stock news by MarketWatch. The company’s Market capitalization was $440.61M with the total Outstanding Shares of 196.78M. Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Can it hold?The stem cell developer decided to wisely take advantage of a soaring share price to raise funds.The FDA has given the company's lead drug platform a potential leg up in development.The stem cell pioneer announced an update with its most important collaborator.An investment bank analyst predicts off-the-hook gains from Athersys' "off-the-shelf" stem cell treatments.ATHX earnings call for the period ending June 30, 2020.ATHX earnings call for the period ending March 31, 2020.ATHX earnings call for the period ending September 30, 2019.ATHX earnings call for the period ending June 30, 2019.ATHX earnings call for the period ending March 31, 2019.ATHX earnings call for the period ending December 31, 2019.Athersys Inc. is a biopharmaceutical company that is focused in the field of regenerative medicine. View real-time stock prices and stock quotes for a full financial overview. Emerging Trends, Regional Analysis, Segments, Prime … Real time Athersys (ATHX) stock price quote, stock graph, news & analysis. Insiders buying/selling: Athersys (NASDAQ:ATHX) In the past three months, Athersys insiders have bought 630.77% more of their company’s stock than they have sold.
Its revenue has been derived from corporate collaborations, license agreements, and government grants. Investing Basics Investing in stocks, bonds, option and other financial instruments involve risks and may not be suitable for everyone. Our system considers the available information about the company and then compares it to all the other stocks we have data on to get a percentile-ranked value. Find the latest Athersys, Inc. (ATHX) stock quote, history, news and other vital information to help you with your stock trading and investing. In-depth view of key statistics and finances for ATHERSYS, INC. (ATHX) on MSN Money. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients, including those suffering from serious conditions with unmet medical needs. Athersys, Inc. () Stock Market info Recommendations: Buy or sell Athersys, Inc. stock? Find the latest analyst research for Athersys, Inc. Common Stock (ATHX) at Nasdaq.com.
Athersys, Inc., belongs to Healthcare sector and Biotechnology industry.